Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | PRKCA | P17252 | 4/20 | 0.68 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.68 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.68 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.68 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.64 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.64 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.63 |
| ▸ | FABP3 | P05413 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25906604 | 1.00 | ALDH1A1 (0.79) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL25449045 | 1.00 | ALDH1A1 (0.79) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL29306783 | 1.00 | ALDH1A1 (0.79) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL26021857 | 1.00 | ALDH1A1 (0.79) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL25818841 | 0.97 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL15369111 | 0.97 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL26208578 | 0.97 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL25818802 | 0.97 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL1080161 | 0.95 | ALDH1A1 (0.87) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL18159452 | 0.92 | ALDH1A1 (0.75) | ALDH1A1LMNAPRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226025-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20240226028-A1 | LYOPHILIZATION METHODS FOR PREPARING LIPID FORMULATED THERAPEUTICS | MODERNATX, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240207444-A1 | LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING PHENYLALANINE HYDROXYLASE AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-06-27 | — | — | US | disclosed |
| US-20240207374-A1 | LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING GLUCOSE-6-PHOSPHATASE AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-06-27 | — | — | US | disclosed |
| US-11827877-B2 | Compositions and methods for genomic editing by insertion of donor polynucleotides | CRISPR THERAPEUTICS AG (CH) | 2023-11-28 | — | — | US | disclosed |
| US-11801227-B2 | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | MODERNATX, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11802144-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230331806-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-10-19 | — | — | US | disclosed |
| US-20230190761-A1 | METHYLENE BLUE STABILIZED MRNA COMPOSITIONS | MODERNATX, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207374-A1 | LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING GLUCOSE-6-PHOSPHATASE AND USES THEREOF | G6PC1, GNPDA1, GPI | ALDH1A1 2322/4885LMNA 1648/4885PRKCA 432/4885 |
| US-20230331806-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RBM17, RTCB, RBM22 | ALDH1A1 3701/4885LMNA 1421/4885PRKCA 2831/4885 |
| US-20240226028-A1 | LYOPHILIZATION METHODS FOR PREPARING LIPID FORMULATED THERAPEUTICS | LIPA, LIPC, PLIN3 | ALDH1A1 3270/4885LMNA 170/4885PRKCA 1149/4885 |
| US-20240226025-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA | MMAB, NSUN3, MSH6 | ALDH1A1 1756/4885LMNA 1905/4885PRKCA 1080/4885 |
| US-20240207444-A1 | LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING PHENYLALANINE HYDROXYLASE AND USES THEREOF | PAH, SARNP, ABHD16A | ALDH1A1 768/4885LMNA 2182/4885PRKCA 1312/4885 |
| US-11801227-B2 | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | CFTR, SLC47A1, TMEM205 | ALDH1A1 3662/4885LMNA 2139/4885PRKCA 2270/4885 |
| US-20230190761-A1 | METHYLENE BLUE STABILIZED MRNA COMPOSITIONS | LMNB2, NSUN2, RNMT | ALDH1A1 2168/4885LMNA 39/4885PRKCA 2962/4885 |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | ALDH1A1 3952/4885LMNA 248/4885PRKCA 2008/4885 |
| US-11802144-B2 | Circular RNA compositions and methods | RBM17, RTCB, RBM22 | ALDH1A1 3701/4885LMNA 1421/4885PRKCA 2831/4885 |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | ALDH1A1 3952/4885LMNA 248/4885PRKCA 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.